The role of antibodies in tuberculosis diagnosis, prophylaxis and therapy : a review from the ESGMYC study group
Melkie, Solomon Tibebu (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Arias, Lilibeth (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Farroni, Chiara (National Institute for Infectious Diseases-IRCCS L. Spallanzani)
Jankovic Makek, Mateja (University Clinical Centre Zagreb)
Goletti, Delia (National Institute for Infectious Diseases-IRCCS L. Spallanzani)
Vilaplana, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Universitat Autònoma de Barcelona

Data:	2022
Resum:	Tuberculosis (TB) is still responsible for the deaths of >1 million people yearly worldwide, and therefore its correct diagnosis is one of the key components of any TB eradication programme. However, current TB diagnostic tests have many limitations, and improved diagnostic accuracy is urgently needed. To improve the diagnostic performance of traditional serology, a combination of different Mycobacterium tuberculosis (MTB) antigens and different antibody isotypes has been suggested, with some showing promising performance for the diagnosis of active TB. Given the incomplete protection conferred by bacille Calmette-Guérin (BCG) vaccination against adult pulmonary TB, efforts to discover novel TB vaccines are ongoing. Efficacy studies from advanced TB vaccines designed to stimulate cell-mediated immunity failed to show protection, suggesting that they may not be sufficient and warranting the need for other types of immunity. The role of antibodies as tools for TB therapy, TB diagnosis and TB vaccine design is discussed. Finally, we propose that the inclusion of antibody-based TB vaccines in current clinical trials may be advisable to improve protection. Despite being controversial, antibodies could play a role in the diagnosis of active TB, LTBI and treatment response monitoring. Antibodies could also help when administered as passive transfer and in the protection generated by new TB vaccine candidates.
Ajuts:	Ministerio de Sanidad y Consumo CB06/06/0031
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	European Respiratory Review, Vol. 31 (march 2022) , ISSN 1600-0617

DOI: 10.1183/16000617.0218-2021
PMID: 35264411

14 p, 690.6 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats